An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
← catalyst calendarNCT06023030 · readout ≤ 103 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
240estimated
Sites
104
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-28 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with Drug Related Serious Infections
measured Up to 64 Weeks
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed